Author Interviews, Gender Differences, HPV / 16.09.2019 Interview with: Dr. Ashish A. Deshmukh UT Health School of Public Health Houston What is the background for this study? Response: The HPV vaccination is recommended for females and males for prevention of 6 cancers (cervical, oropharyngeal, anal, penile, vaginal, and vulvar). Nearly 43,000 HPV-associated cancer cases are diagnosed every year in the US. Yet, it is extremely unfortunate and something that continues to bother us that HPV vaccination coverage remains low (50% in 2018) in the US and completion rate is nearly 5% lower in boys. Different from some industrialized nations where vaccination policy is school-based, vaccination policy in the US is clinic-based and parents are generally responsible for making vaccination decisions for their children. Generally, there are two main factors that drive parents’ decision-making: (1) how much knowledge they have of HPV and (2) recommendation from a healthcare professional. We analyzed the National Cancer Institute’s Health Information National Trend Survey (HINTS) of over 6000 participants focusing on their knowledge of HPV and HPV vaccination and whether participants received any vaccination recommendation from their health care provider.  (more…)
Author Interviews, Cancer Research, Race/Ethnic Diversity / 18.04.2019 Interview with: Farhad Islami, MD PhD Scientific Director, Surveillance Research American Cancer Society, Inc. Atlanta, GA 30303 What is the background for this study? Response: Despite a continuous decline in cervical cancer incidence rates, earlier studies reported an increase in cervical adenocarcinoma incidence rates. However, those reports had major limitations, as they did not account for changes in hysterectomy prevalence and used cancer occurrence data covering only 10%-12% of the U.S. population (which may not be representative of the entire population, especially racial/ethnic minorities). Further, the most recent study examined the trends by age and histology through 2010. We examined contemporary trends in cervical cancer incidence rates in the U.S. (1999-2015) by age, race/ethnicity, major histological subtypes, and stage at diagnosis using up-to-date nationwide data after accounting for hysterectomy prevalence. (more…)
Author Interviews, BMJ, Cancer Research, HPV, Vaccine Studies / 05.03.2014 Interview with: Dr Julia Brotherton Victorian Cytology Service, Melbourne, Victoria, Australia Dr Elizabeth Crowe The University of Queensland, School of Population Health, Brisbane, Australia NHS Borders, Department of Public Health, Melrose, Scotland, UK Prof. David Whiteman Group Leader / Department Coordinator QIMR Berghofer Medical Research Institute Royal Brisbane Hospital, QLD 4029 What are the main findings of the study? 1.       We conducted a case-control study in which we retrieved the HPV vaccination histories of young Australian women who were notified to the Pap smear registry with high-grade cervical lesions or with other types of cervical lesions, and compared them with the vaccination histories of women whose Pap smears showed only normal cytology. 2.       We found that women with high grade cervical lesions were significantly less likely than women with normal cytology to have received 3 doses of the quadrivalent HPV vaccine, equivalent to a vaccine effectiveness of 46%. 3.       The vaccine effectiveness among 15-19 year old women was even higher at 57%. We believe this reflects the fact that HPV16 causes an even higher proportion of high grade disease in young women due to its higher oncogenicity and shorter latent period. 4.       The HPV vaccine had 34% effectiveness against other cervical lesions (i.e. those not proven to be high grade lesions on histology). 5.       We also observed that 2 doses of the vaccine were 21% effective in preventing both high grade lesions and other grade lesions. (more…)